Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Cannabidiol (CBD), a non-psychoactive compound derived from the Cannabis sativa plant, has attracted scientific interest for its potential therapeutic effects in various inflammatory and autoimmune skin diseases, including psoriasis. Several preclinical studies have demonstrated that CBD exerts anti-inflammatory, immunomodulatory, and antiproliferative effects on keratinocytes, the predominant cell type involved in the pathogenesis of psoriasis. In vitro research suggests that CBD can inhibit the proliferation of human keratinocytes and reduce the production of pro-inflammatory cytokines such as TNF-α and IL-6, which are involved in the inflammatory cascade of psoriasis (Wilkinson & Williamson, 2007). Additionally, animal studies have shown that topical administration of cannabinoids can reduce inflammation and symptoms in models of skin inflammation. However, robust clinical evidence in humans is limited. A few small-scale clinical trials and case reports have noted improvements in skin symptoms after topical CBD use, but these studies often lack controls and have small sample sizes (Palmieri et al., 2019). As of now, no large randomized controlled trials have conclusively established the efficacy or safety of CBD for psoriasis treatment in humans. Thus, while there is a growing scientific rationale and preliminary data supporting its use, the overall strength of the evidence remains modest.

More about Cannabidiol
More about Psoriasis

Other ingredients used for Psoriasis

Other health conditions supported by Cannabidiol

Products containing Cannabidiol